Completed × Inflammatory Breast Neoplasms × Epirubicin × Clear all Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Phase 1/2 Completed
93 enrolled
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Phase 2 Completed
47 enrolled 13 charts
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Phase 2 Completed
123 enrolled 8 charts
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
PEGASE07
Phase 3 Completed
174 enrolled
GeparX
Phase 2 Completed
780 enrolled
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Phase 3 Completed
961 enrolled
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Phase 3 Completed
1,856 enrolled
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Phase 3 Completed
1,500 enrolled
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Phase 2 Completed
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
Phase 1 Completed
15 enrolled